AstraZeneca plc (LON:AZN) Receives Average Recommendation of “Hold” from Brokerages
AstraZeneca plc (LON:AZN) has received an average rating of “Hold” from the nineteen research firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is GBX 6,553.85 ($85.64).
A number of research firms have recently issued reports on AZN. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. UBS Group raised their price target on shares of Crowdstrike from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday. They noted that the move was a valuation call. Shore Capital restated a “house stock” rating on shares of in a research report on Friday, July 12th. Bryan, Garnier & Co restated a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Finally, Kepler Capital Markets set a €11.00 ($12.79) price target on shares of E.On and gave the stock a “buy” rating in a research report on Monday, May 13th.
AZN stock traded down GBX 12 ($0.16) during mid-day trading on Tuesday, hitting GBX 6,390 ($83.50). 1,748,279 shares of the company were exchanged, compared to its average volume of 2,310,000. The firm has a market cap of $83.82 billion and a P/E ratio of 33.63. The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57. AstraZeneca has a twelve month low of GBX 5,312 ($69.41) and a twelve month high of GBX 6,634 ($86.68). The stock’s fifty day moving average is GBX 6,299.76.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.